A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2015/08/15
-
Journal
-
Indian UGC (journal)
-
Refrences41
-
Citations56
-
Márcia Waddington Cruz
-
Merril D. Benson
Cite
Waddington Cruz, Márcia, and Merril D. Benson. “A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis”. Neurology and Therapy, vol. 4, no. 2, 2015, pp. 61-79, https://doi.org/10.1007/s40120-015-0031-3.
Waddington Cruz, M., & Benson, M. D. (2015). A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurology and Therapy, 4(2), 61-79. https://doi.org/10.1007/s40120-015-0031-3
Waddington Cruz M, Benson MD. A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurology and Therapy. 2015;4(2):61-79.
Journal Categories
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Neurology
Diseases of the nervous system
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings | Journal of Neurology, Neurosurgery & Psychiatry |
| 89 | 2015 |
The effect of tafamidis on the QTc interval in healthy subjects | British Journal of Clinical Pharmacology |
| 15 | 2015 |
| Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil | Amyloid |
| 14 | 2012 |
| The diflunisal trial: update on study drug tolerance and disease progression | Amyloid |
| 15 | 2011 |
| 10.1212/01.WNL.0000132966.36437.12 | Neurology |
| 2004 |
Refrences Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry 16
is the most frequently represented among the references in this article. It primarily includes studies from Neurology The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009–2019) | Revue Neurologique |
| 2024 | |
| Improved Efficient Synthesis of the Transthyretin Amyloid Fibril Inhibitor Tafamidis | Pharmaceutical Chemistry Journal |
| 2023 | |
Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition | Arquivos de Neuro-Psiquiatria |
| 2023 | |
Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal | Orphanet Journal of Rare Diseases |
| 1 | 2023 |
| Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy | Drug, Healthcare and Patient Safety |
| 2023 |
Citations Analysis
The category
Medicine: Medicine (General) 16
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment and was published in 2016. The most recent citation comes from a 2024 study titled Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009–2019). This article reached its peak citation in 2020, with 15 citations. It has been cited in 42 different journals, 28% of which are open access. Among related journals, the Amyloid cited this research the most, with 5 citations. The chart below illustrates the annual citation trends for this article.